Wiebke Theess

机构：Roche (Switzerland)

发表论文 8 篇 · 总被引 430 次 · h-index 5

代表论文

• Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial (2021 · Journal of Allergy and Clinical Immunology · 被引 319)
• Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis (2022 · Journal of Allergy and Clinical Immunology · 被引 68)
• Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial* (2022 · Critical Care Medicine · 被引 24)
• Development of AITC‐induced dermal blood flow as a translational in vivo biomarker of TRPA1 activity in human and rodent skin (2020 · British Journal of Clinical Pharmacology · 被引 11)
• Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review (2025 · Respiratory Research · 被引 9)
• Extensive changes in the airway epithelial landscape in COPD uncovered by snRNA-seq and gene regulatory network analysis. (2026)